Progress, Potential, and Possibilities Podcast / Show

Send us Fan Mail
What if we could take something as simple - and seemingly ordinary - as a urine sample, measure thousands of chemical signals within it, and use artificial intelligence to recognize the metabolic fingerprint of disease?

And what if, instead of looking for one specific biomarker, we could train an algorithm to recognize the complex pattern created by an entire disease state?

That is the premise behind Luventix ( https://www.luventix.com/ ), a technology company developing AI and machine-learning diagnostic models based on quantitative analysis of urine.

Today's guest, Dejan Nenov, comes to this problem from a somewhat unusual direction.

He's not a traditional biotech entrepreneur.

Dejan is a computer engineer, technology entrepreneur, investor and longtime software executive who has spent more than three decades building companies across fields ranging from telecommunications and cybersecurity to enterprise software, consumer electronics and data architecture.

Dejan has been involved with companies that have collectively returned more than $3.5 billion to investors - and he's now turned his attention to one of the most complicated systems imaginable:

the human body.

At Luventix, the idea is to use gas chromatography to generate a quantitative representation of the metabolic state contained within a urine sample, and then use machine learning to identify patterns associated with disease, treatment response, and potentially treatment-related toxicity.

Today on Progress, Potential, and Possibilities, we're going to explore whether the next generation of medical diagnostics may be less about finding a single molecule - and more about teaching machines to recognize the incredibly complex biological patterns hidden in our own chemistry.

#AI #ArtificialIntelligence #HealthcareAI #MedicalAI #Diagnostics #HealthTech #DigitalHealth #Biotechnology #Biotech #PrecisionMedicine #UrineDiagnostics #DiseaseDetection #MachineLearning #Metabolomics #Biomarkers #MedicalInnovation #FutureOfHealthcare #HealthInnovation #ClinicalDiagnostics #Luventix #ProgressPotentialAndPossibilities
Support the show

Send us Fan Mail
We tend to think that a new medicine's journey begins in the laboratory and ends when the FDA approves it. But there's an enormous part of that journey that most people never see: Who decides which medicines a company should acquire? Which ones are worth billions of dollars? How do you turn an approved drug into a successful commercial product - and ultimately get it into the hands of patients? Today we're going behind the scenes of that process.

Jane Gonnerman is Executive Vice President of Strategy and Corporate Development at Collegium Pharmaceutical ( https://www.collegiumpharma.com/ ), a leading biopharmaceutical company focused on improving the lives of people living with serious and often misunderstood conditions, where she is helping guide the company's long-term growth strategy and business development initiatives.

Before joining Collegium in 2025, Jane served as Senior Vice President of Rare Disease at Amgen following the landmark $28 billion acquisition of Horizon Therapeutics - one of the largest biotechnology acquisitions in recent history. Prior to that, she served as Senior Vice President of Corporate Development and Chief of Staff to Horizon's CEO, playing a central role in the company's corporate strategy, partnerships, acquisitions, and ultimately its successful sale to Amgen.

Earlier in her career, Jane spent more than fifteen years at Bain & Company, becoming a Partner in the firm's healthcare practice where she advised many of the world's leading life science organizations on strategy, growth, organizational transformation, and innovation.

Jane holds an MBA from the University of Chicago Booth School of Business along with dual bachelor's degrees in Mathematics and Statistics from the University of Florida.

Today we'll explore what it really takes to build successful biopharmaceutical companies, how commercialization has become as innovative as science itself, and why strategy may ultimately determine which medical breakthroughs change patients' lives.

#CollegiumPharmaceutical #JaneGonnerman #PharmaceuticalIndustry #Biotech #Biopharma #Pharma #DrugDevelopment #DrugCommercialization #PharmaInnovation #CorporateStrategy #CorporateDevelopment #BusinessDevelopment #PharmaMergers #HealthcareInnovation #DrugDiscovery #RareDisease #ADHD #PainManagement #DrugDelivery #JORNAYPM #AZSTARYS #XtampzaER #Belbuca #Nucynta #ProgressPotentialAndPossibilities
Support the show

Send us Fan Mail
Most of us think of medicine as something we take every day - a statin, a blood pressure pill, or perhaps a monthly injection. But what if those lifelong treatments eventually become obsolete? What if one carefully targeted gene edit could dramatically reduce your risk of heart disease for decades? 

Dr. Trevor Martin, Ph.D. is the Co-Founder and Chief Executive Officer of Mammoth Biosciences ( https://mammoth.bio/ ), a pioneering biotechnology company developing next-generation CRISPR genome editing technologies for potentially curative medicines. He co-founded the company in 2017 alongside Nobel Prize-winning CRISPR pioneer Dr. Jennifer Doudna and an interdisciplinary team of leading scientists with the goal of building more precise, versatile, and clinically practical gene editing systems.

Dr. Martin earned his undergraduate degree in Molecular Biology with honors from Princeton University before completing a Ph.D. in Genetics and Statistics at Stanford University, where his research focused on quantitative genetics, genomics, and computational biology. His scientific background in statistics and genetics has shaped Mammoth's unique approach to developing smaller CRISPR enzymes capable of reaching tissues and diseases that have been difficult to target with first-generation technologies.

Under Dr. Martin's leadership, Mammoth has grown into one of the world's leading CRISPR companies, raising more than $465 million, achieving a valuation exceeding $1 billion, and establishing strategic collaborations with companies including Vertex Pharmaceuticals, Bayer, and Regeneron Pharmaceuticals.

Today, Mammoth is advancing a pipeline of in vivo gene editing therapies, including programs targeting cardiovascular disease through permanent editing of the APOC3 gene - a potential one-time treatment approach aimed at dramatically reducing triglycerides and long-term cardiovascular risk. Beyond therapeutics, the company's CRISPR platform also extends into diagnostics and genome engineering technologies that may reshape medicine over the coming decades.

Dr. Martin has been recognized as an EY Entrepreneur of the Year®, Forbes 30 Under 30, and Fortune 40 Under 40 honoree for his contributions to biotechnology and scientific entrepreneurship.

#CRISPR #GeneEditing #TrevorMartin #MammothBiosciences #JenniferDoudna #Biotechnology #GenomeEditing #HeartDisease #Longevity #FutureOfMedicine #PrecisionMedicine #Genetics #DNA #HealthInnovation #MedicalBreakthrough #CardiovascularDisease #SciencePodcast #Biotech #Innovation #ProgressPotentialPossibilities
Support the show

Send us Fan Mail
The same technologies that could transform medicine, agriculture, and manufacturing could also reshape global security. Understanding the future of biotechnology requires scientists who can bridge discovery, engineering, and responsibility.

Today on Progress, Potential, and Possibilities, we’re joined by a true pioneer at the nexus of biotechnology and national security. Dr. Jessica Dymond, Ph.D is the Vice President of Technology at In-Q-Tel ( https://www.iqt.org/ ), a not-for-profit venture fund that invests in companies advancing the strategic priorities of U.S. Intelligence Community, where she provides technical and strategic leadership to accelerate emerging biotechnologies that address some of the most critical challenges to national and global security.

Before In-Q-Tel, Dr. Dymond served as Chief Scientist for Physical and Life Sciences at the Johns Hopkins University Applied Physics Laboratory, where she led an interdisciplinary portfolio spanning biological sensing, genomic surveillance, microbiome engineering, and synthetic biology. She founded the Lab’s Biological Sciences group and spearheaded initiatives to anticipate, assess, and mitigate emerging biological threats while strengthening global health security.

Formally trained as a synthetic biologist, Dr. Dymond earned her Ph.D. from the Johns Hopkins University School of Medicine, completed a postdoctoral fellowship in functional genomics at the U.S. Department of Agriculture, and has contributed to groundbreaking research, including the design of synthetic yeast genomes and combinatorial genomic diversity. She also serves on the editorial board of Synthetic Biology from Oxford University Press.

Dr. Dymond’s career embodies the bridge between cutting-edge science, technology strategy, and real-world impact - protecting health, security, and society through innovation at the molecular frontier.

#SyntheticBiology #Biotechnology #Biosecurity #FutureOfBiology #GenomeEngineering #Genomics #DNA #GeneticEngineering #ArtificialBiology #BiologyRevolution #LifeSciences #FutureTechnology #EmergingTechnologies #ScienceInnovation #Innovation #NationalSecurity #GlobalHealthSecurity #PandemicPreparedness #AIandBiology #Bioengineering #SyntheticGenomics #CRISPR #GeneticTechnology #HealthcareInnovation #ScientificDiscovery #TechnologyTrends #ProgressPotentialAndPossibilities
Support the show

Send us Fan Mail
We spend billions of dollars each year funding scientific discovery - but what happens if the people making those discoveries can't communicate them? Today we're exploring why communication may be just as important as innovation itself, and why some of the world's brightest scientists never receive the recognition their work deserves.

Nancy Ancowitz ( https://www.nancyancowitz.com/ ) is career strategist, executive presentation coach, author, educator, and one of the country's leading experts on helping professionals communicate their expertise with clarity, confidence, and authenticity.

Nancy has spent more than two decades teaching communication, presentation skills, and career strategy at New York University ( https://www.sps.nyu.edu/faculty-directory/10734-nancy-h-ancowitz.html ) while coaching everyone from emerging professionals to CEOs on how to translate knowledge into influence. 

Nancy is the author of the acclaimed Self-Promotion for Introverts® ( https://www.amazon.com/Self-Promotion-Introverts-Quiet-Guide-Getting-ebook/dp/B00394U8DS?ref_=ast_author_dp&th=1&psc=1 ), recognized by Publishers Weekly as one of the year's best business books, as well as Zoom to Success and Business Writing: Say More With Less.

Before launching her coaching practice, Nancy spent twelve years on Wall Street, leading marketing communications for multibillion-dollar businesses as a Vice President at JPMorgan Chase and earlier at Citibank, where she was recognized for innovation in global marketing communications. Along the way, her insights have appeared in The New York Times, The Wall Street Journal, and Psychology Today, and she has spoken at organizations ranging from the National Institutes of Health to the Federal Reserve Bank of New York.

Today, we're taking Nancy's work in a slightly different direction. Here on Progress, Potential and Possibilities, we spend much of our time with scientists, physicians, engineers, biotech founders, and technology innovators who are developing extraordinary breakthroughs - but often struggle to communicate those breakthroughs beyond their laboratories, companies, and research institutions.

In an age where groundbreaking discoveries compete with endless streams of information, social media, and artificial intelligence, is communication becoming just as important as innovation itself? Can brilliant ideas change the world if their creators never learn to tell their story?

We explore why communication, authenticity, and thoughtful self-promotion may be some of the most underrated drivers of scientific and technological progress.

#ScienceCommunication #STEM #Innovation #Leadership #PublicSpeaking #CommunicationSkills #Scientists #Biotechnology #ArtificialIntelligence #InnovationLeadership #Entrepreneurship #CareerDevelopment #PresentationSkills #PersonalBranding #AuthenticLeadership #ProgressPotentialPossibilities
Support the show